Limits...
Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells.

Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, Choi YH, Tuschl T, Bosio A - Stem Cells (2011)

Bottom Line: Using quantitative whole genome miRNA microarray and sequencing-based profiling, we found that between 109 (CD133(+) ) and 216 (CD34(-) CD133(-) ) miRNAs were expressed.In conclusion, the miRNAs expressed differentially between the CD133(+) and CD34(+) CD133(-) cells are involved in inhibition of differentiation, prevention of apoptosis, and cytoskeletal remodeling.These results are highly relevant for stem cell-based therapies with CD133(+) cells and delineate for the first time how the stem cell character of CD133(+) cells is defined by the expression of specific miRNAs.

View Article: PubMed Central - PubMed

Affiliation: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.

Show MeSH
Validation of microarray data via Solexa sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). (A): Venn diagram showing miRNAs detected with over 100 counts (sequencing) or onefold over background (array data) in CD133+ and/or CD34+CD133− cells. (B): The ratios of CD133+ counts versus CD34+CD133− counts for the 18 significantly differentially expressed miRNA are displayed for two donors. miRNAs that were present with less than 100 counts are marked with ‡. (C): The expression levels of six miRNAs were also determined by qRT-PCR using the miScript system for two (miR-125b, miR-551b) or three donors. RN5S1 was used for normalization.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3116150&req=5

fig04: Validation of microarray data via Solexa sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). (A): Venn diagram showing miRNAs detected with over 100 counts (sequencing) or onefold over background (array data) in CD133+ and/or CD34+CD133− cells. (B): The ratios of CD133+ counts versus CD34+CD133− counts for the 18 significantly differentially expressed miRNA are displayed for two donors. miRNAs that were present with less than 100 counts are marked with ‡. (C): The expression levels of six miRNAs were also determined by qRT-PCR using the miScript system for two (miR-125b, miR-551b) or three donors. RN5S1 was used for normalization.

Mentions: Ninety-five miRNAs were sequenced with over 100 counts compared with 135 miRNAs detected onefold over background on all arrays. The overlap between the two groups was 81 miRNAs detected with both methods (Fig. 4A).


Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells.

Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, Choi YH, Tuschl T, Bosio A - Stem Cells (2011)

Validation of microarray data via Solexa sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). (A): Venn diagram showing miRNAs detected with over 100 counts (sequencing) or onefold over background (array data) in CD133+ and/or CD34+CD133− cells. (B): The ratios of CD133+ counts versus CD34+CD133− counts for the 18 significantly differentially expressed miRNA are displayed for two donors. miRNAs that were present with less than 100 counts are marked with ‡. (C): The expression levels of six miRNAs were also determined by qRT-PCR using the miScript system for two (miR-125b, miR-551b) or three donors. RN5S1 was used for normalization.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3116150&req=5

fig04: Validation of microarray data via Solexa sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). (A): Venn diagram showing miRNAs detected with over 100 counts (sequencing) or onefold over background (array data) in CD133+ and/or CD34+CD133− cells. (B): The ratios of CD133+ counts versus CD34+CD133− counts for the 18 significantly differentially expressed miRNA are displayed for two donors. miRNAs that were present with less than 100 counts are marked with ‡. (C): The expression levels of six miRNAs were also determined by qRT-PCR using the miScript system for two (miR-125b, miR-551b) or three donors. RN5S1 was used for normalization.
Mentions: Ninety-five miRNAs were sequenced with over 100 counts compared with 135 miRNAs detected onefold over background on all arrays. The overlap between the two groups was 81 miRNAs detected with both methods (Fig. 4A).

Bottom Line: Using quantitative whole genome miRNA microarray and sequencing-based profiling, we found that between 109 (CD133(+) ) and 216 (CD34(-) CD133(-) ) miRNAs were expressed.In conclusion, the miRNAs expressed differentially between the CD133(+) and CD34(+) CD133(-) cells are involved in inhibition of differentiation, prevention of apoptosis, and cytoskeletal remodeling.These results are highly relevant for stem cell-based therapies with CD133(+) cells and delineate for the first time how the stem cell character of CD133(+) cells is defined by the expression of specific miRNAs.

View Article: PubMed Central - PubMed

Affiliation: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.

Show MeSH